Medexus Pharmaceuticals Inc (MDP.TO) saw its stock price drop by 1.34% today, closing at CA$5.16. This decline reflects investor concerns, especially given the lack of recent positive news. With a market cap of about CA$161 million, the company is facing challenges that may be impacting its stock performance.
Investor takeaway: The absence of recent positive developments and the current market dynamics may be contributing to Medexus's stock decline, signaling caution for potential investors.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medexus Pharmaceuticals Inc stock declines by 1.34%
With a market cap of CA$161 million and a profit margin of -2.41%, Medexus is under pressure as it navigates a challenging market landscape.
Bull case
Investors may find potential in Medexus's ongoing projects and future announcements, particularly regarding their GRAFAPEX product, which has shown promise in earlier reports.
Bear case
The recent drop in stock price, along with a negative profit margin of -2.41%, raises concerns about the company's financial health and its ability to generate sustainable profits.
Market Performance Overview
Medexus Pharmaceuticals Inc's stock closed down 1.34% in the last trading session, reflecting a broader trend of investor caution. The company hasn't released any significant news lately that could have influenced a positive market response.
Advertisement
Financial Health and Investor Sentiment
With a market cap of CA$161 million and a negative profit margin, Medexus is under scrutiny from investors. The lack of strong fiscal performance indicators may be contributing to the stock's downward trend. Investors should consider these metrics before making decisions.
Looking Ahead
As Medexus continues to face operational challenges, upcoming announcements related to their product pipeline, especially GRAFAPEX, could play a crucial role in shaping investor sentiment. Staying informed about these developments will be important for potential investors considering MDP.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
